Key terms
About BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BLUE news
Yesterday
5:35pm ET
bluebird bio, Inc. Class Action: Levi & Korsinsky LLP Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 – BLUE
Mar 27
7:29am ET
Bluebird Bio price target lowered to $4 from $5 at BofA
Mar 26
8:49pm ET
Bluebird Bio price target lowered to $3 from $4 at Wells Fargo
Mar 26
8:02pm ET
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Healthequity (HQY) and Bluebird Bio (BLUE)
Mar 26
7:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
Mar 26
5:25pm ET
Hold Rating on Bluebird Bio Amidst Gradual Patient Starts and Funding Steps
Mar 26
8:05am ET
Options Volatility and Implied Earnings Moves Today, March 26, 2024
Mar 21
2:38am ET
Optimistic Outlook for Bluebird Bio: Buy Rating Affirmed on Extended Financial Runway and Profitability Prospects
Mar 19
8:56am ET
Bluebird Bio price target lowered to $1.68 from $3 at Wedbush
Mar 14
12:50pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 14
11:41am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Mar 11
8:15am ET
Bluebird Bio signs Medicaid outcomes-based agreement for Lyfgenia
Mar 01
1:20am ET
Strong Market Potential for Bluebird Bio’s Lyfgenia Backed by High Demand and Differentiation Factors
Feb 01
12:40am ET
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Alcon (ALC)
Jan 11
1:31am ET
Market Perform Rating Maintained for Bluebird Bio Amidst New Therapy Launch and Financial Uncertainty
Jan 10
5:43am ET
Hold Rating on Bluebird Bio Amid Launch Optimism and Financial Prudence
Jan 09
4:55am ET
William Blair Reaffirms Their Hold Rating on Bluebird Bio (BLUE)
Jan 08
8:48am ET
Bluebird Bio provides update on commercial launch, announces factoring deal
Mar 26
2:47pm ET
bluebird bio Reports Certain Financial Statements Should No Longer Be Relied Upon; Expects To Continue To Report Substantial Doubt Regarding Ability To Continue As A Going Concern - Investors With Losses Encouraged To Contact Kehoe Law Firm, P.C. - BLUE
Mar 26
1:57pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses to Contact the Firm
BLUE Financials
Key terms
Ad Feedback
BLUE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BLUE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range